ArticleTranslational andrology and urology2026
Association between systemic inflammatory response index and the prognosis of patients with localized and advanced renal cell carcinoma: a systematic review and meta-analysis.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renal cell carcinoma (RCC) is a common and aggressive urological malignancy with a complex tumor microenvironment that may influence systemic inflammation. This review aimed to comprehensively explore the association between the systemic inflammatory response index (SIRI) and prognosis in patients with renal cell carcinoma (RCC) through a systematic review and meta-analysis. Methods: Following the PRISMA guidelines, we systematically searched PubMed, Embase, Web of Science, and the Cochrane Library up to September 2025. Studies investigating the predictive value of SIRI [SIRI = (neutrophil count × monocyte count)/lymphocyte count] for overall survival (OS), cancer-specific survival (CSS), or progression-free survival (PFS) in patients with localized and advanced RCC were included. Two researchers independently performed article screening, data extraction, and quality assessment. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were pooled using a random-effects model with Review Manager 5.4.1 software. The I Results: A total of 10 studies involving 5,314 patients were included. Meta-analysisresults showed that a higher SIRI was significantly associated with shorter OS (HR =2.47, 95% CI: 1.85-3.29, P<0.00001), although there was high heterogeneity (I Conclusions: This study demonstrates that a higher SIRI is a potential predictor of adverse prognosis (including OS, CSS, and PFS) in patients with RCC. As an easily accessible inflammatory marker, SIRI may have important clinical value in the risk stratification of RCC, but the findings still need to be further verified by prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.